Analysis of Circulating Tumor DNA
Circulating tumor DNA (ctDNA) analysis is currently gaining momentum as an innovative methodology for characterizing the tumor genome and monitoring therapeutic efficacy in the multifocal, genetically and spatially heterogeneous plasma cell malignancy, multiple myeloma (MM). Circulating cell-free DNA (cfDNA), which consists of a combination of DNA derived from both tumor and normal cells, is present in extracellular bodily fluids. The presence of ctDNA within this admixture has been demonstrated recently in MM. In this chapter, we describe the routinely utilized methodology for the extraction and longitudinal analysis of specific mutations present in ctDNA derived from peripheral blood plasma of MM patients.
Key wordsCirculating tumor DNA Circulating cell-free nucleic acids Cell-free DNA Multiple myeloma Peripheral blood plasma Droplet digital PCR Liquid biopsy
- 9.Plagnol V et al. (2015) Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform. J Clin Oncol. 33(15)Google Scholar
- 11.Demetri GD et al (2013) Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REC) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: correlating genotype with clinical outcomes. J Clin Oncol 31(15):10503Google Scholar
- 12.Demetri GD, et al. (2013) Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST. Cancer Res. 73(8)Google Scholar